Cybin D/B/A Helus Pharma HELP

Set alert

Price alert · HELP

All alert types
9.23 USD +0.43 +4.89%

As of Nov 3, 11:54 AM ET

Bid
9.22 × 2
Ask
9.29 × 2
8.94 Day range 9.57
3.76 52-week range 15.15
YTD
+12.84%
1 year
+37.15%
Open
9.00
Prev close
8.80
Mkt cap
675.16M
Vol
595.61K
Avg vol
1.75M
EPS
-4.15
P/E
0.00
Div yield
0.00%
More statistics
Low
8.94
High
9.57
Forward P/E
-7.55
Beta
0.63
Short ratio
1.59
Inst. own
41.29%
Dividend
0.00
Ex-div date
Earnings
Nov 12, 2026
50-d avg
10.70
200-d avg
7.11
1y target
40.24

1Y chart

Chart tools
Interval

Events in this range
  • Nov 13, 2025Earnings: -1.39; estimate -0.74; surprise -87.84%
  • Feb 13, 2026Earnings: -0.99243; estimate -0.53; surprise -87.25%
  • Apr 13, 2026Rating: TD Cowen · — → Buy
  • Jun 30, 2026Earnings: -0.95583; estimate -1.04; surprise 8.09%
  • Jul 1, 2026Rating: Canaccord Genuity · Buy → Buy
  • Jul 9, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Jul 27, 2026Rating: Wells Fargo · — → Overweight
  • Aug 14, 2026Earnings: -0.91; estimate -0.83607; surprise -8.84%
  • Aug 20, 2026Rating: TD Cowen · Buy → Buy
  • Sep 18, 2026Rating: Barclays · — → Overweight
Signals (54)
NameDateAgo
MACD: Sell SignalNov 2, 20261 day ago
MACD: Buy SignalOct 28, 20266 days ago
SMA: BearishOct 5, 20264 weeks ago
MACD: Sell SignalAug 28, 20262 months ago
RSI: OverboughtAug 19, 20262 months ago
RSI: OverboughtAug 12, 20262 months ago
MACD: Buy SignalAug 4, 20263 months ago
RSI: OverboughtAug 4, 20263 months ago
MACD: Sell SignalJul 31, 20263 months ago
RSI: OverboughtJul 30, 20263 months ago
RSI: OverboughtJul 21, 20263 months ago
RSI: OverboughtJul 17, 20263 months ago
RSI: OverboughtJul 10, 20263 months ago
SMA: BullishJul 7, 20263 months ago
SMA: BearishJul 6, 20264 months ago
SMA: BullishJun 25, 20264 months ago
RSI: OverboughtJun 25, 20264 months ago
MACD: Buy SignalJun 15, 20264 months ago
MACD: Sell SignalJun 3, 20265 months ago
MACD: Buy SignalJun 1, 20265 months ago

Newest 20 of 54.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 40.24 +336.0% upside
Target (low)
15.08
Target (mean)
40.24
Target (high)
69.16
Ratings (0m) 11 11 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy10
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 10
  • 2 months ago 10
  • 3 months ago 9

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

HELP analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.9448-1.15 – -0.569-1.65+42.9%00.0%5
Next quarter-0.8782-1.07 – -0.638-1.36+35.6%00.0%5
Current year-3.71-4.43 – -2.86-5.91+37.4%00.0%4
Next year-2.54-3.04 – -2.04-3.71+31.4%11.07M0.0%2

Upgrades and downgrades

The latest rating changes

HELP analyst upgrades and downgrades
DateFirmActionFromTo
Sep 18, 2026BarclaysInitiated—Overweight
Aug 20, 2026TD CowenMaintainedBuyBuy
Jul 27, 2026Wells FargoInitiated—Overweight
Jul 9, 2026HC Wainwright & Co.MaintainedBuyBuy
Jul 1, 2026Canaccord GenuityMaintainedBuyBuy
Apr 13, 2026TD CowenInitiated—Buy
Mar 2, 2026HC Wainwright & Co.MaintainedBuyBuy
Dec 3, 2025GuggenheimMaintainedBuyBuy
Nov 20, 2025Canaccord GenuityMaintainedBuyBuy
Nov 14, 2025HC Wainwright & Co.MaintainedBuyBuy